Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > TOP STORIES
TOP STORIES
-
REGULATORY Patient Group Flags Risks of Inconsistent Decisions on OTC-Like Drug Charges
August 28, 2026
-
REGULATORY Pharma Seeks Inflation-Liked Price Hikes, Freeze on Patent-Period Cuts for 2027 Revision
August 27, 2026
-
BUSINESS Belite Bio Eyes Japan Filing for Stargardt Drug within 3 Months
August 26, 2026
-
REGULATORY Japan Approves Takeda’s Orzeyful, Insmed’s Brinsupri and More Drugs
August 25, 2026
-
COMMENTARY Beyond Dupixent: Next Wave of COPD Biologics Takes Shape
August 25, 2026
-
BUSINESS MSD Launches RSV Antibody Enflonsia in Japan without NHI Listing
August 24, 2026
-
BUSINESS Sawai’s Solo Tenelia Copy Raises Patent Questions Ahead of December Listing
August 21, 2026
-
BUSINESS DT-Axis Charts Path to 2nd-Stage DTx Approval with Depression App
August 21, 2026
-
BUSINESS Amvuttra Key to Alnylam Japan’s 25%-Plus CAGR Goal through 2030
August 20, 2026
-
REGULATORY Japan Panel to Discuss Approval of 6 NMEs, Leqembi SC on Aug. 26
August 20, 2026
-
REGULATORY DPP Lawmaker Calls for Inflation Relief in 2027 Off-Year Drug Price Revision
August 19, 2026
-
REGULATORY CEA Review Group Wraps Up Technical Debate, Urges More Company Access
August 19, 2026
-
BUSINESS Keytruda Keeps Top Spot in Japan in April-June as Mounjaro Zooms: IQVIA
August 19, 2026
-
REGULATORY Japan Panel to Weigh Keytruda SC, J&J Psoriasis Pill among 6 NMEs on Aug. 24
August 18, 2026
-
REGULATORY Japan Calls for APOE Testing before Leqembi, Kisunla Treatment
August 18, 2026
-
REGULATORY Trazenta Draws 8 Generic Entrants as Japan Clears New DPP-4 Copies
August 17, 2026
-
ORGANIZATION EFPIA Executive Hails Japan’s Honebuto as “Blueprint” for Europe
August 17, 2026
-
BUSINESS Takeda Snares US Approval for Orzeyful in Narcolepsy Type 1
August 7, 2026
-
REGULATORY Nakai Tapped as MHLW’s Top Pharmacy Officer; Ohara to Steer Drug Pricing Reform
August 7, 2026
-
REGULATORY Sarclisa SC, Joenja, Kineret, and 7 More Drugs Bound for NHI Listing
August 6, 2026
ページ
More than a year after Dupixent (dupilumab) became the first antibody therapy approved for COPD in Japan, drug makers are…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…